Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy

Fig. 2

Confirmation of dsDNA binding to DMONs and evaluation of the innate immune activation of dsDNA@DMONs. A The dsDNA loading capacity of dsDNA@DMONs at various weight ratios of dsDNA: DMONs with a fixed concentration of DMONs (Si: 100 μg/mL). B Images of agarose gel electrophoresis of free dsDNA and dsDNA@DMONs at various weight ratios of dsDNA: DMONs, with Trans2K Plus DNA Marker. C The luciferase secretion levels of RAW-Lucia ISG cells treated with dsDNA (2.4 μg/mL), DMONs (Si: 6 μg/mL) and dsDNA@DMONs (Si: 6 μg/mL) with various weight ratios of dsDNA: DMONs of 1:1 to 5:1. D The luciferase secretion levels of RAW-Lucia ISG cells treated with dsDNA and dsDNA: DMONs of various concentrations. Data are shown as mean ± SEM (n ≥ 3). P value was calculated by unpaired Student's t-test in A, C and D. (*p < 0.05; ***p < 0.001)

Back to article page